Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sorin Gains Distribution Rights, Minority Stake In Respicardia’s remedē Sleep Apnea Device

This article was originally published in The Gray Sheet

Executive Summary

Sorin’s $20 million investment will help Respicardia continue the U.S. pivotal trial of the remedē implantable phrenic nerve stimulator for sleep apnea and give Sorin exclusive rights to distribute the device in select European countries, where it has a CE mark but has yet to be launched.

You may also be interested in...



Starts & Stops: Respicardia Puts Sleep Apnea Device PAS On Snooze

Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions over the past month. This edition takes a closer look at Respicardia, which has cut short the post-approval study of its implantable sleep apnea device study.

Respicardia's remedē Neurostimulator Improves Sleep Apnea Symptoms In Pivotal Trial

The implantable neurostimulation system works automatically and continuously during every hour of sleep and does not depend on patient adherence, which has been a major limitation of continuous positive airway pressure therapy.

Research Briefs: Robotic Leg; Bone-Mineral Density Tests; Diabetes; Sleep Apnea

New prosthetic leg can receive signals from the patient’s nervous system to improve control. Study shows repeated bone-mineral density tests do not improve the prediction of osteoporosis-related injury.

Related Content

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT033442

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel